News

SORT BY YEAR
13 December, 2018

Ally Bridge Portfolio News – WuXi AppTec Completes Secondary Listing in HKEx After Fast-Track A-Share IPO

HONG KONG and SHANGHAI, December 12, 2018– WuXi AppTec Co., Ltd. (Stock code: 603259.SH/2359.HK) today announced the successful secondary listing on the Main Board of the Hong Kong Stock Exchange,  just seven months after it went public in Shanghai via a fast-tracked listing. Based on the offer price of HK$68 per share, the net proceeds to […]

Read More
13 December, 2018

Ally Bridge Portfolio News – Wuxi Apptec Successfully Prices Hong Kong Offering in Stormy market

BioCentury – Dec 8, 2018 Despite global trade headwinds and a choppy market for biopharma stocks in China, WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) successfully price its Hong Kong listing within its proposed range Friday, raising HK$7.9 billion ($1 billion) based on its proposed number of shares. The listing is the third for a unit […]

Read More
6 December, 2018

Ally Bridge Portfolio News – TESARO reaches agreement to be acquired by GSK

LONDON and WALTHAM, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) — GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion). The proposed transaction significantly strengthens GSK’s pharmaceutical business, […]

Read More
15 November, 2018

Ally Bridge Portfolio News – Vapotherm Shares Soar 14.29% in Trading Debut

Vapotherm Inc, which provides noninvasive breathing aids to treat respiratory distress, raised $56 million by offering 4 million shares at $14. The stock started trading on the New York Stock Exchange Wednesday, under the ticker symbol “VAPO”. BofA Merrill Lynch and William Blair were bookrunners on the deal with Canaccord and BTIG acting as co-managers. Proceeds […]

Read More
1 November, 2018

Ally Bridge Portfolio News – Axonics IPO Opened Strong at $16.05/Share (+7%), against a fragile market

October 30, 2018 Business Wire RVINE, Calif.–(BUSINESS WIRE)–Axonics Modulation Technologies, Inc. (“Axonics”), a medical technology company focused on the design, development and commercialization of innovative and minimally invasive sacral neuromodulation (“SNM”) solutions for the treatment of overactive bladder (“OAB”), fecal incontinence (“FI”), and urinary retention (“UR”), today announced the pricing of its initial public offering […]

Read More
1 November, 2018

Ally Bridge Portfolio News – Innovent Biologics hikes on HK debut amid cloudy market sentiments

October 31, 2018 ENDPOINTS NEWS Innovent Biologics has surged on its closely watched Hong Kong IPO, hitting a 21% rise at one point and ending the day at 18.6% above its IPO price after raising a record setting $421 million. The Suzhou-based unicorn, which earned a valuation of $2 billion with its pipeline of 17 […]

Read More
19 September, 2018

BioCentury – WUXI APPTEC QUEUES UP FOR HONG KONG LISTING

SEP 18, 2018  | BioCentury Less than five months after its IPO in Shanghai, WuXi AppTec Co. Ltd. (Shanghai:603259) proposed Tuesday to list on the Hong Kong stock exchange in an offering underwritten by Morgan Stanley Asia, Huatai Financial Holdings (Hong Kong) and Goldman Sachs (Asia). WuXi announced in July its plan to list in Hong […]

Read More
19 September, 2018

Ally Bridge Portfolio News – WuXi AppTec Said to File for $1 Billion-Plus Hong Kong Offering

September 18, 2018, Bloomberg Report WuXi AppTec Co., the Chinese contract medical researcher, has submitted an application for a Hong Kong share sale, according to people with knowledge of the matter. The offering could raise more than $1 billion, the people said, asking not to be identified because the information is private. The Shanghai-listed shares […]

Read More
19 September, 2018

BioCentury – HUA’S INSTITUTIONAL ADVANTAGE

HUA’S INSTITUTIONAL ADVANTAGE HOW DIABETES COMPANY HUA NAVIGATED VOLATILE HONG KONG MARKET TO PRICE IPO 8:17 AM CST | SEP 15, 2018 | BIOCENTURY The same market forces that drove Hua Medicine Ltd. to reduce the size of its Hong Kong IPO tempered participation by retail investors, which could help keep the Shanghai diabetes company’s […]

Read More
19 September, 2018

Ally Bridge Portfolio News – Hua Medicine Raises $110mn in Hong Kong IPO

SEP 14, 2018 | BioCentury Diabetes company Hua Medicine Ltd. (HKSE:2552) raised HK$867 million ($110.5 million) in an IPO through the sale of 104.8 million shares at HK$8.28. EVP and CFO George Lin said the offering, which priced at the low end of its HK$8.28-HK$9.28 range, values the company at HK$8.7 billion ($1.1 billion). Underwriters […]

Read More